Actionable FGFR1 and BRAF mutations in adult circumscribed gliomas.
Elena TrisoliniDounia El WardighiMarine GiryPriscilla BernardiRenzo Luciano BoldoriniKarima MokhtariMarc SansonPublished in: Journal of neuro-oncology (2019)
We report actionable targets, including frequent FGFR1 mutation in optic-pathway PA that makes them excellent candidates to anti-FGFR therapies, and BRAF non-canonical mutations in PA.